CISPLATIN + AZD-1775 In Breast Cancer

NCT03012477 PHASE2 COMPLETED Results posted

This research study is studying a combination of drugs as a possible treatment for triple-negative breast cancer that has spread to other areas of the body. The names of the study interventions involved in this study are: * Cisplatin * AZD1775

Details

Lead sponsor	Dana-Farber Cancer Institute
Phase	PHASE2
Status	COMPLETED
Enrolment	34
Start date	Wed Jan 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Nov 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Triple-negative Metastatic Breast Cancer

Interventions

• Cisplatin
• AZD1775

Countries

United States